Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1858 - Afatinib dose intensity and clinical efficacy in advanced EGFR-mutated non-small cell lung cancer: UK multicentre real-life data

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Carlos Escriu

Citation

Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292

Authors

C. Escriu1, M. Sallam2, L.P. del Carpio3, N. Tokaca4, L. Solway5, R. Shah6, A. Fouzia1, Q. Ghafoor5, S. Popat7, P.E. Postmus8

Author affiliations

  • 1 Medical Oncology, The Clatterbridge Cancer Center, CH63 4JY - Merseyside/GB
  • 2 School Of Medicine, University of Liverpool, Liverpool/GB
  • 3 Medical Oncology, Hospital de la Santa Creu i Sant Pau, 8026 - Barcelona/ES
  • 4 Medical Oncology, The Royal Marsden NHS Foundation Trust, London/GB
  • 5 Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham/GB
  • 6 Medical Oncology, Maidstone and Tumbridge Wells NHS Trust, Maidstone/GB
  • 7 Medicine, The Francis Crick Institute, NW1 1AT - London/GB
  • 8 Respiratory Diesease, Leiden University Medical Center (LUMC), 2300 RC - Leiden/NL
More

Abstract 1858

Background

The second-generation afatinib has shown longer Progression-Free Survival (PFS) than gefitinib in the first line treatment of advanced EGFR mutated lung cancer, and has excellent penetration into the central nervous system. It is licensed at a starting dose of 40mg/day, but in real-life practice dose reductions due to toxicity are common. As for other targeted agents, it is questionable if dose selection should be based on biological active dose instead of maximum tolerable dose. Here we aimed to identify the frequency of afatinib dose reductions and analyse their impact in survival outcomes in the UK real-life population.

Methods

Patients with EGFR-mutated lung cancer treated with afatinib between April 2014 and December 2017 in four UK centres were retrospectively identified. The frequency of dose reductions and response rates was quantified. Dose Intensity (DI; average daily dose over the total treatment period) was calculated and patients were grouped into DI > 30mg/day and DI ≤ 30mg/day; PFS and Overall Survival (OS) curves were plotted.

Results

98 patients were identified. The median treatment duration was 8.5 months (range 01.-42.7), and mean DI 30.6mg/day. 85 patients started at 40mg/day and 13 at 30mg/day. They required dose reductions in 65% (n = 55) and 46% (n = 6), respectively. The starting dose did not influence response rates. 50 patients (51%) received a DI ≤ 30 and 48 patients (49%) received a DI > 30. A lower DI did not significantly influence PFS (HR 0.65(0.37-1.14); p = 0.127) or OS (HR 0.58(0.28-1.20); p = 0.14), but showed a trend to better outcomes. Patients with brain metastasis (n = 11(22%) DI ≤ 30 and n = 14(29%) DI > 30) had similar clinical outcomes regardless of DI, and patients that required a reduction to the lowest dose of 20mg/day (n = 28) achieved similar PFS (HR 0.58(0.3-1.14); p = 0.113) and OS (HR 0.41 (0.16-1.08); p = 0.062) as the rest (n = 70).

Conclusions

Our results suggest equal clinical efficacy in patients treated with a lower DI of afatinib, and a reduced need for dose reductions in patients starting at 30mg/day. Prospective tolerability and efficacy of afatinib starting at 30mg/day will be quantified in a phase II UK study.

Clinical trial identification

Legal entity responsible for the study

The Clatterbridge Cancer Centre NHS Trust.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

R. Shah: Advisory board: Boehringer Ingelheim. Q. Ghafoor: Consultancy: Roche, AstraZeneca, Boehringer Ingelheim, Pfizer. S. Popat: Honoraria, consulting and research funding: Boehringer Ingelheim. P.E. Postmus: Paid member of advisory board: Boehringer Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.